Zkusit zdarma
Oculis Holding AG

Oculis Holding AG

OCS
Cena:
$ 29.49
-1.51 (-4.87%)
Valuace
70
Růst
0
Zdraví
50

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí

close

OCULIS TO SHOWCASE TRANSFORMATIVE LATE-STAGE PIPELINE IN NEURO-OPHTHALMOLOGY AND OPHTHALMOLOGY AT THE 2026 J.P. MORGAN HEALTHCARE CONFERENCE

08-01-2026
ZUG, SWITZERLAND, JAN. 08, 2026 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (“...

OCULIS ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION GRANTED TO PRIVOSEGTOR FOR TREATMENT OF OPTIC NEURITIS

06-01-2026
ZUG, SWITZERLAND, JAN. 06, 2026 (GLOBE NEWSWIRE) -- BREAKTHROUGH THERAPY DESIGNATION GRANTED TO PRIV...

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

09-12-2025
ZUG, SWITZERLAND, DEC. 09, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATIONS RELATE TO THE VESTING...

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

03-12-2025
ZUG, SWITZERLAND, DEC. 03, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATION RELATES TO THE VESTING...

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

28-11-2025
ZUG, SWITZERLAND, NOV. 28, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATION RELATES TO THE VESTING...

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

18-11-2025
ZUG, SWITZERLAND, NOV. 18, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATION RELATES TO THE PURCHAS...

OCULIS REPORTS Q3 2025 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

10-11-2025
OCULIS ACCELERATES ITS PORTFOLIO DEVELOPMENT WITH PRIVOSEGTOR MOVING INTO THE PIONEER PIVOTAL PROGRA...

OCULIS TO PARTICIPATE IN UPCOMING NOVEMBER INVESTOR CONFERENCES

05-11-2025
ZUG, SWITZERLAND, NOV. 05, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (“...

OCULIS ANNOUNCES OVERSUBSCRIBED $110 MILLION FINANCING TO ACCELERATE PRIVOSEGTOR DEVELOPMENT

30-10-2025
ZUG, SWITZERLAND, OCT. 30, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS; XICE: OCS) (“O...

OCULIS ANNOUNCES OVERSUBSCRIBED $110 MILLION FINANCING TO ACCELERATE PRIVOSEGTOR DEVELOPMENT

30-10-2025
ZUG, SWITZERLAND, OCT. 30, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS; XICE: OCS) (“O...

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

14-10-2025
ZUG, SWITZERLAND, OCT. 14, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED TWO NOTIFICATIONS RELATE TO THE EXE...

OCULIS TO SPOTLIGHT TRANSFORMATIVE LATE-STAGE PIPELINE AT EYECELERATOR AND AAO 2025

14-10-2025
ZUG, SWITZERLAND, OCT. 14, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (“...

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

08-10-2025
ZUG, SWITZERLAND, OCT. 08, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATION RELATES TO THE VESTING...

OCULIS ACCELERATES PRIVOSEGTOR INTO REGISTRATIONAL TRIALS IN ACUTE OPTIC NEURITIS, PIONEERING THE PATH FOR A POTENTIAL FIRST-IN-CLASS NEUROPROTECTIVE THERAPY

06-10-2025
SUCCESSFUL MEETING WITH FDA ENABLES ADVANCEMENT INTO PIVOTAL DEVELOPMENT WITH PRIVOSEGTOR IN ACUTE O...

OCULIS PUBLISHES NOTIFICATION OF TRANSACTIONS BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

26-09-2025
ZUG, SWITZERLAND, SEPT. 26, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATION RELATES TO TRADES ENT...

NEXE INNOVATIONS EXPANDS PRODUCT PORTFOLIO WITH SEVERAL NEW SKUS IN COLLABORATION WITH NORTH AMERICAN OCS PARTNER

24-09-2025
NEXE EXPANDS WITH 4 NEW COMPOSTABLE COFFEE POD SKUS, INCLUDING PUMPKIN, VIA MAJOR OCS PARTNER—DRIV...

OCULIS ANNOUNCES PRESENTATION OF PHASE 2 ACUITY TRIAL RESULTS WITH PRIVOSEGTOR IN ACUTE OPTIC NEURITIS AT ECTRIMS

22-09-2025
ZUG, SWITZERLAND, SEPT. 22, 2025 (GLOBE NEWSWIRE) -- PRIVOSEGTOR ACUITY TRIAL SHOWED IMPROVED LCVA A...

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

09-09-2025
ZUG, SWITZERLAND, SEPT. 09, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATIONS RELATE TO THE VESTIN...

OCULIS AND EURETINA ANNOUNCE THE WINNER OF THE RAMIN TADAYONI AWARD 2025

04-09-2025
ZUG, SWITZERLAND, SEPT. 04, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (...

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

03-09-2025
ZUG, SWITZERLAND, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATION RELATES TO THE VESTIN...

OCULIS TO PRESENT CLINICAL TRIAL RESULTS IN DIABETIC MACULAR EDEMA AND ACUTE OPTIC NEURITIS AT OPHTHALMOLOGY CONFERENCES

01-09-2025
PHASE 2 ACUITY TRIAL RESULTS FOR PRIVOSEGTOR (OCS-05) IN ACUTE OPTIC NEURITIS TO BE PRESENTED IN EUR...

OCULIS TO PARTICIPATE IN UPCOMING SEPTEMBER INVESTOR CONFERENCES

28-08-2025
ZUG, SWITZERLAND, AUG. 28, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (“...

OCULIS APPOINTS MARK KUPERSMITH, M.D., AND SEBASTIAN WOLF, M.D.

25-08-2025
ZUG, SWITZERLAND, AUG. 25, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (“...

OCULIS REPORTS Q2 2025 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

21-08-2025
ZUG, SWITZERLAND, AUG. 21, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (“...

OCULIS TO PARTICIPATE IN UPCOMING H.C WAINWRIGHT 5TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE

12-08-2025
ZUG, SWITZERLAND, AUG. 12, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS; XICE: OCS) (“O...

OCULIS UPSIZED LOAN FACILITY TO ACCESS UP TO CHF 100 MILLION

01-08-2025
ZUG, SWITZERLAND, AUG. 01, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS; XICE: OCS) (“O...

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

09-07-2025
ZUG, SWITZERLAND, JULY 09, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATION RELATES TO THE VESTING...

OCULIS PUBLISHES RESULTS OF 2025 ANNUAL GENERAL MEETING

05-06-2025
ZUG, SWITZERLAND, JUNE 05, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / XICE: OCS) (“...

OCULIS PUBLISHES NOTIFICATIONS OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

03-06-2025
ZUG, SWITZERLAND, JUNE 03, 2025 (GLOBE NEWSWIRE) -- THE ATTACHED NOTIFICATIONS RELATE TO THE VESTING...

OCULIS TO PARTICIPATE IN UPCOMING JUNE INVESTOR CONFERENCES

03-06-2025
ZUG, SWITZERLAND, JUNE 03, 2025 (GLOBE NEWSWIRE) -- OCULIS HOLDING AG (NASDAQ: OCS / ICX: OCS.IC) (...

close

Dokumenty nejsou k dispozici

preloader